Study: Preoperative Treatment for Early-Stage NSCLC

[Barb73]

http://www.medicalnewstoday.com/articles/109424.php

Excerpt on NSCLC from complete article on various new findings regarding cancer:

. . . . . . . . .

Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study. [Abstract number: 7557; Poster number 34G]

Sunday, June 1

Authors: N. Altorki, M. Guarino, P. Lee, H. I. Pass, E. Filip, T. Bauer, D. Roychowdhury, T. Zaks, L. Ottesen, D. Yankelevitz

Dr. Nasser Altorki presented final data from a Phase II clinical trial showing that a drug that stops blood vessel growth (angiogenesis) to tumors is safe and highly effective for the treatment of early-stage non-small cell lung cancer. Pazopanib works by blocking the action of vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which both work by growing bloods vessels that supply nutrition to tumors. Prior to surgery to remove their tumors, 87 percent of the 26 subjects tested had a significant reduction in tumor growth.

. . . . . . . . .

(Medical News Today, Cancer/Oncology, Lung Cancer, June 2, 2008)

Disclaimer:

The information contained in these articles may or may not be in agreement with my own opinions. They are not posted as medical advice of any kind